pDONR223-MAP2K1 Citations (2)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-MAP2K1
| Articles |
|---|
| Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition. Yao W, Oh YT, Deng J, Yue P, Deng L, Huang H, Zhou W, Sun SY. J Biol Chem. 2016 Oct 7;291(41):21694-21702. Epub 2016 Aug 30. PubMed |
| Copper Chelation Inhibits BRAF(V600E)-Driven Melanomagenesis and Counters Resistance to BRAF(V600E) and MEK1/2 Inhibitors. Brady DC, Crowe MS, Greenberg DN, Counter CM. Cancer Res. 2017 Nov 15;77(22):6240-6252. doi: 10.1158/0008-5472.CAN-16-1190. Epub 2017 Oct 6. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.